Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390362 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
A Phase 3 study, sponsored by Nationwide Children's Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT02390362: Clinical Trial Phase 3 study, sponsored by Nationwide Children's Hospital.
NCT02390362 is a Phase 3 study that was terminated before completion, run by Nationwide Children's Hospital. The registered enrollment target is 3 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02390362, a Phase 3 study, was terminated before completion, sponsored by Nationwide Children's Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective than MMF in maintaining remission in children with frequent relapsing or steroid dependent nephrotic syndrome who have had one relapse while receiving MMF. We will conduct a randomized study comparing two Rituximab infusions and continued MMF treatment. We plan to enroll 64 to have a comparater group of 58 (29 in each arm).
Interventions
- DRUG Rituximab
- DRUG MMF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-01-18 |
| Phase | Phase 3 |
Why NCT02390362 stopped before completion
NCT02390362 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT02390362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02390362 about?
NCT02390362 is a clinical study titled "Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome". We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective than MMF in maintaining remission in children with frequent relapsing or steroid dependent nephrotic syndrome who have had one relapse while receiving MMF. We will conduct a randomized study comparing two Rituxim...
What is the current status of trial NCT02390362?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2015-01. Estimated completion is 2017-01-18.
What interventions are being tested in trial NCT02390362?
The interventions under investigation include: Rituximab (DRUG), MMF (DRUG).
Who is sponsoring clinical trial NCT02390362?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02390362's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia